Annual D&A
$692.00 K
-$35.00 K-4.81%
31 December 2023
Summary:
Lineage Cell Therapeutics annual depreciation & amortization is currently $692.00 thousand, with the most recent change of -$35.00 thousand (-4.81%) on 31 December 2023. During the last 3 years, it has fallen by -$1.35 million (-66.06%). LCTX annual D&A is now -91.77% below its all-time high of $8.41 million, reached on 31 December 2014.LCTX Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$141.00 K
-$1000.00-0.70%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly depreciation & amortization is currently $141.00 thousand, with the most recent change of -$1000.00 (-0.70%) on 30 September 2024. Over the past year, it has dropped by -$35.00 thousand (-19.89%). LCTX quarterly D&A is now -95.99% below its all-time high of $3.51 million, reached on 31 December 2014.LCTX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$633.00 K
-$35.00 K-5.24%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM depreciation & amortization is currently $633.00 thousand, with the most recent change of -$35.00 thousand (-5.24%) on 30 September 2024. Over the past year, it has dropped by -$57.00 thousand (-8.26%). LCTX TTM D&A is now -92.47% below its all-time high of $8.41 million, reached on 31 December 2014.LCTX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.8% | -19.9% | -8.3% |
| 3 y3 years | -66.1% | -29.1% | -37.8% |
| 5 y5 years | -78.9% | -81.5% | -79.0% |
LCTX Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -66.1% | at low | -29.1% | at low | -37.8% | at low |
| 5 y | 5 years | -78.9% | at low | -81.5% | at low | -79.0% | at low |
| alltime | all time | -91.8% | +465.8% | -96.0% | +166.7% | -92.5% | +411.7% |
Lineage Cell Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $141.00 K(-0.7%) | $633.00 K(-5.2%) |
| June 2024 | - | $142.00 K(-18.9%) | $668.00 K(-4.0%) |
| Mar 2024 | - | $175.00 K(0.0%) | $696.00 K(+0.6%) |
| Dec 2023 | $692.00 K(-4.8%) | $175.00 K(-0.6%) | $692.00 K(+0.3%) |
| Sept 2023 | - | $176.00 K(+3.5%) | $690.00 K(-2.4%) |
| June 2023 | - | $170.00 K(-0.6%) | $707.00 K(-1.8%) |
| Mar 2023 | - | $171.00 K(-1.2%) | $720.00 K(-1.0%) |
| Dec 2022 | $727.00 K(-16.7%) | $173.00 K(-10.4%) | $727.00 K(-2.4%) |
| Sept 2022 | - | $193.00 K(+5.5%) | $745.00 K(-0.8%) |
| June 2022 | - | $183.00 K(+2.8%) | $751.00 K(-1.8%) |
| Mar 2022 | - | $178.00 K(-6.8%) | $765.00 K(-12.4%) |
| Dec 2021 | $873.00 K(-57.2%) | $191.00 K(-4.0%) | $873.00 K(-14.2%) |
| Sept 2021 | - | $199.00 K(+1.0%) | $1.02 M(-19.7%) |
| June 2021 | - | $197.00 K(-31.1%) | $1.27 M(-21.5%) |
| Mar 2021 | - | $286.00 K(-14.9%) | $1.61 M(-20.8%) |
| Dec 2020 | $2.04 M(-32.0%) | $336.00 K(-25.2%) | $2.04 M(-16.3%) |
| Sept 2020 | - | $449.00 K(-17.5%) | $2.44 M(-11.3%) |
| June 2020 | - | $544.00 K(-23.4%) | $2.75 M(-7.0%) |
| Mar 2020 | - | $710.00 K(-3.3%) | $2.96 M(-1.5%) |
| Dec 2019 | $3.00 M(-8.3%) | $734.00 K(-3.5%) | $3.00 M(-0.3%) |
| Sept 2019 | - | $761.00 K(+1.3%) | $3.01 M(-1.4%) |
| June 2019 | - | $751.00 K(-0.4%) | $3.05 M(-3.5%) |
| Mar 2019 | - | $754.00 K(+1.3%) | $3.16 M(-3.3%) |
| Dec 2018 | $3.27 M(-0.7%) | $744.00 K(-7.6%) | $3.27 M(-3.4%) |
| Sept 2018 | - | $805.00 K(-6.5%) | $3.39 M(-0.8%) |
| June 2018 | - | $861.00 K(-0.2%) | $3.42 M(+2.2%) |
| Mar 2018 | - | $863.00 K(+0.3%) | $3.34 M(+1.4%) |
| Dec 2017 | $3.30 M(-30.7%) | $860.00 K(+3.5%) | $3.30 M(+1.0%) |
| Sept 2017 | - | $831.00 K(+5.6%) | $3.26 M(-1.8%) |
| June 2017 | - | $787.00 K(-3.8%) | $3.32 M(-13.3%) |
| Mar 2017 | - | $818.00 K(-1.0%) | $3.83 M(-19.4%) |
| Dec 2016 | $4.76 M(-24.9%) | $826.00 K(-7.3%) | $4.76 M(-14.2%) |
| Sept 2016 | - | $891.00 K(-31.3%) | $5.55 M(-11.0%) |
| June 2016 | - | $1.30 M(-25.6%) | $6.23 M(-4.1%) |
| Mar 2016 | - | $1.74 M(+7.9%) | $6.50 M(+2.6%) |
| Dec 2015 | $6.33 M(-24.7%) | $1.62 M(+2.4%) | $6.33 M(-23.0%) |
| Sept 2015 | - | $1.58 M(+1.0%) | $8.23 M(-0.7%) |
| June 2015 | - | $1.56 M(-0.9%) | $8.29 M(-0.9%) |
| Mar 2015 | - | $1.58 M(-55.1%) | $8.36 M(-0.6%) |
| Dec 2014 | $8.41 M(+112.8%) | $3.51 M(+114.3%) | $8.41 M(+29.3%) |
| Sept 2014 | - | $1.64 M(+0.3%) | $6.50 M(+14.6%) |
| June 2014 | - | $1.63 M(+0.6%) | $5.67 M(+17.7%) |
| Mar 2014 | - | $1.62 M(+1.2%) | $4.82 M(+22.0%) |
| Dec 2013 | $3.95 M(+39.5%) | $1.61 M(+98.5%) | $3.95 M(+26.2%) |
| Sept 2013 | - | $809.00 K(+3.4%) | $3.13 M(+2.2%) |
| June 2013 | - | $782.40 K(+3.5%) | $3.06 M(+3.4%) |
| Mar 2013 | - | $755.90 K(-3.8%) | $2.96 M(+4.6%) |
| Dec 2012 | $2.83 M | $785.40 K(+6.0%) | $2.83 M(+12.2%) |
| Sept 2012 | - | $740.60 K(+8.4%) | $2.53 M(+0.9%) |
| June 2012 | - | $683.00 K(+9.4%) | $2.50 M(+1.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $624.40 K(+30.8%) | $2.47 M(+4.4%) |
| Dec 2011 | $2.36 M(+154.6%) | $477.40 K(-33.5%) | $2.36 M(-2.7%) |
| Sept 2011 | - | $717.40 K(+10.7%) | $2.43 M(+25.4%) |
| June 2011 | - | $648.30 K(+24.3%) | $1.94 M(+34.7%) |
| Mar 2011 | - | $521.40 K(-4.2%) | $1.44 M(+55.0%) |
| Dec 2010 | $928.80 K(+2584.4%) | $544.10 K(+141.6%) | $928.80 K(+135.5%) |
| Sept 2010 | - | $225.20 K(+51.0%) | $394.40 K(+121.9%) |
| June 2010 | - | $149.10 K(+1333.7%) | $177.70 K(+381.6%) |
| Mar 2010 | - | $10.40 K(+7.2%) | $36.90 K(+6.3%) |
| Dec 2009 | $34.60 K(+107.2%) | $9700.00(+14.1%) | $34.70 K(+3.9%) |
| Sept 2009 | - | $8500.00(+2.4%) | $33.40 K(-134.3%) |
| June 2009 | - | $8300.00(+1.2%) | -$97.50 K(+283.9%) |
| Mar 2009 | - | $8200.00(-2.4%) | -$25.40 K(-251.2%) |
| Dec 2008 | $16.70 K(-108.8%) | $8400.00(-106.9%) | $16.80 K(-108.3%) |
| Sept 2008 | - | -$122.40 K(-252.2%) | -$203.10 K(+175.6%) |
| June 2008 | - | $80.40 K(+59.5%) | -$73.70 K(-49.7%) |
| Mar 2008 | - | $50.40 K(-123.8%) | -$146.60 K(-22.6%) |
| Dec 2007 | -$189.20 K(-814.0%) | -$211.50 K(-3121.4%) | -$189.30 K(+225.8%) |
| Sept 2007 | - | $7000.00(-6.7%) | -$58.10 K(-285.0%) |
| June 2007 | - | $7500.00(-2.6%) | $31.40 K(-4.3%) |
| Mar 2007 | - | $7700.00(-109.6%) | $32.80 K(+23.3%) |
| Dec 2006 | $26.50 K(+314.1%) | -$80.30 K(-183.2%) | $26.60 K(-75.4%) |
| Sept 2006 | - | $96.50 K(+984.3%) | $108.00 K(+771.0%) |
| June 2006 | - | $8900.00(+493.3%) | $12.40 K(+153.1%) |
| Mar 2006 | - | $1500.00(+36.4%) | $4900.00(-23.4%) |
| Dec 2005 | $6400.00(-99.4%) | $1100.00(+22.2%) | $6400.00(-41.8%) |
| Sept 2005 | - | $900.00(-35.7%) | $11.00 K(-40.5%) |
| June 2005 | - | $1400.00(-53.3%) | $18.50 K(-33.0%) |
| Mar 2005 | - | $3000.00(-47.4%) | $27.60 K(-97.4%) |
| Dec 2004 | $1.05 M(+29.4%) | $5700.00(-32.1%) | $1.05 M(-18.7%) |
| Sept 2004 | - | $8400.00(-20.0%) | $1.29 M(-13.8%) |
| June 2004 | - | $10.50 K(-99.0%) | $1.50 M(-10.9%) |
| Mar 2004 | - | $1.02 M(+314.5%) | $1.68 M(+107.3%) |
| Dec 2003 | $810.60 K(+60.0%) | $247.10 K(+14.8%) | $810.60 K(+14.2%) |
| Sept 2003 | - | $215.30 K(+11.3%) | $709.70 K(-13.6%) |
| June 2003 | - | $193.50 K(+25.1%) | $821.40 K(+49.0%) |
| Mar 2003 | - | $154.70 K(+5.8%) | $551.10 K(+8.8%) |
| Dec 2002 | $506.70 K(+71.4%) | $146.20 K(-55.3%) | $506.70 K(-15.8%) |
| Sept 2002 | - | $327.00 K(-525.8%) | $602.10 K(+105.4%) |
| June 2002 | - | -$76.80 K(-169.6%) | $293.10 K(-24.2%) |
| Mar 2002 | - | $110.30 K(-54.3%) | $386.50 K(+30.8%) |
| Dec 2001 | $295.60 K(+291.5%) | $241.60 K(+1242.2%) | $295.60 K(+303.3%) |
| Sept 2001 | - | $18.00 K(+8.4%) | $73.30 K(-1.7%) |
| June 2001 | - | $16.60 K(-14.4%) | $74.60 K(-2.5%) |
| Mar 2001 | - | $19.40 K(+0.5%) | $76.50 K(+1.5%) |
| Dec 2000 | $75.50 K(+26.9%) | $19.30 K(0.0%) | $75.40 K(+34.4%) |
| Sept 2000 | - | $19.30 K(+4.3%) | $56.10 K(+52.4%) |
| June 2000 | - | $18.50 K(+1.1%) | $36.80 K(+101.1%) |
| Mar 2000 | - | $18.30 K | $18.30 K |
| Dec 1999 | $59.50 K | - | - |
FAQ
- What is Lineage Cell Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual D&A year-on-year change?
- What is Lineage Cell Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly D&A year-on-year change?
- What is Lineage Cell Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM D&A year-on-year change?
What is Lineage Cell Therapeutics annual depreciation & amortization?
The current annual D&A of LCTX is $692.00 K
What is the all time high annual D&A for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual depreciation & amortization is $8.41 M
What is Lineage Cell Therapeutics annual D&A year-on-year change?
Over the past year, LCTX annual depreciation & amortization has changed by -$35.00 K (-4.81%)
What is Lineage Cell Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of LCTX is $141.00 K
What is the all time high quarterly D&A for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly depreciation & amortization is $3.51 M
What is Lineage Cell Therapeutics quarterly D&A year-on-year change?
Over the past year, LCTX quarterly depreciation & amortization has changed by -$35.00 K (-19.89%)
What is Lineage Cell Therapeutics TTM depreciation & amortization?
The current TTM D&A of LCTX is $633.00 K
What is the all time high TTM D&A for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM depreciation & amortization is $8.41 M
What is Lineage Cell Therapeutics TTM D&A year-on-year change?
Over the past year, LCTX TTM depreciation & amortization has changed by -$57.00 K (-8.26%)